title: [3rd generation's TKI in lung cancer non-small cell EGFR-mutated having acquired a secondary T790M resistance].
abstract: Activating EGFR mutations discovery and efficacy of 1st generation tyrosine kinase inhibitors (TKI), such as erlotinib or gefitinib, inaugurated the beginning of personalized medicine in the treatment of EGFR-mutated non-small cell lung cancer (NSCLC). However, all patients showed a tumor progression of 10 to 16 months after the onset of TKI therapy related to molecular resistance mechanisms as T790M mutation. Till now, patients suffering from EGFR-mutated NSCLC with acquired resistance have conventional treatment options. Two new 3rd generations' TKI, AZD9291 and rociletinib, are currently being studied in phases 1-3 studies. Preliminary results show relevant therapeutic properties in patients with T790M mutated-EGFR NSCLC. This review aims to highlight these new molecules, their effectiveness and their clinical toxicities in the treatment of advanced stages of NSCLC expressing the T790M mutation.
authors.affiliation: Institut Gustave-Roussy, département d'innovation thérapeutique et d'essais précoces, 94800 Villejuif, France; CHU de Caen, pneumologie et oncologie thoracique, 14000 Caen, France.
authors.forename: Solenn
authors.initials: S
authors.lastname: Brosseau
authors.affiliation: Institut Gustave-Roussy, département d'innovation thérapeutique et d'essais précoces, 94800 Villejuif, France; CHU Clermont-Ferrand, oncologie médicale, 63000 Clermont-Ferrand, France.
authors.forename: Marie
authors.initials: M
authors.lastname: Viala
authors.affiliation: Institut Gustave-Roussy, département d'innovation thérapeutique et d'essais précoces, 94800 Villejuif, France.
authors.forename: Andréa
authors.initials: A
authors.lastname: Varga
authors.affiliation: Institut Gustave-Roussy, département de médecine oncologique, 94800 Villejuif, France.
authors.forename: David
authors.initials: D
authors.lastname: Planchard
authors.affiliation: Institut Gustave-Roussy, département de médecine oncologique, 94800 Villejuif, France.
authors.forename: Benjamin
authors.initials: B
authors.lastname: Besse
authors.affiliation: Institut Gustave-Roussy, département d'innovation thérapeutique et d'essais précoces, 94800 Villejuif, France; Institut Gustave-Roussy, département de médecine oncologique, 94800 Villejuif, France; Université Paris-Sud, 91400 Orsay, France. Electronic address: soria@gustaveroussy.fr.
authors.forename: Jean-Charles
authors.initials: JC
authors.lastname: Soria
mesh_terms: D000178:Acrylamides / Q000627:therapeutic use*; D000814:Aniline Compounds / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics; D018450:Disease Progression; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D066246:ErbB Receptors / Q000235:genetics*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics; D009154:Mutation; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D007211:Indoles
chemical_list: D000178:Acrylamides; D000814:Aniline Compounds; D000970:Antineoplastic Agents; D066246:ErbB Receptors; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; C000596361:osimertinib; D007211:Indoles; C000589977:rociletinib
keywords: AZD9291; Cancer bronchique non à petites cellules; EGFR mutation; Mutation EGFR; Mutation T790M; Non-small cell lung cancer; Rociletinib; Rocilétinib; T790M mutation